Cantor Fitzgerald raises Amgen stock price target on portfolio strength
Cantor Fitzgerald raised Amgen's (AMGN) price target to $440 from $400, citing strong portfolio performance. The stock trades at $413, up 29% YTD. InvestingPro notes its low P/E and PEG ratios. Cantor expects MariTide data in 2027 to sustain momentum. Other firms like Truist and Oppenheimer also raised targets post-positive trial results.
How this was made
The 30-second read
Why it matters
The target raise may prompt short-term buying, but long-term performance will depend on trial results and revenue growth.
Market read
Analyst target adjustments can move the stock and influence sector sentiment.
What to watch
Potential risks from upcoming trial outcomes and competitive pipeline not fully priced in.
Background
Cantor Fitzgerald highlighted Amgen's commercial performance and pipeline updates as reasons for the target increase.
Ticker impact
Cantor Fitzgerald raised its price target on Amgen to $440 from $400, maintaining a Neutral rating.
likely upward pressure as investors price in the higher target
The new $440 target reflects confidence in commercial performance and pipeline progress, which may attract buying interest.
Market effects
Biotech sector may see modest uplift as a major player receives a higher target.
U.S. market sentiment toward large-cap biotech could improve.
Limited to investors tracking Amgen and related biotech peers.
Counterpoint
Some investors may view the target raise as premature given pending trial data.
Key entities
- companyAmgen Inc.
Biopharmaceutical company receiving the price target raise.
- analystCantor Fitzgerald
Research firm that raised the price target.
